Replicon particle vaccination induces non-neutralizing anti-nucleoprotein antibody-mediated control of Crimean-Congo hemorrhagic fever virus

• Published in: npj vaccines 2024-05, Vol.9 (1), p.88-88, Article 88
• Main Authors: Sorvillo, Teresa E., Karaaslan, Elif, Scholte, Florine E. M., Welch, Stephen R., Coleman-McCray, JoAnn D., Genzer, Sarah C., Ritter, Jana M., Hayes, Heather M., Jain, Shilpi, Pegan, Scott D., Bergeron, Éric, Montgomery, Joel M., Spiropoulou, Christina F., Spengler, Jessica R.
• Format: Article
• Language: English
• Subjects: 631/250/590; 631/326/596; Animals; Antibodies; Antigens; Biomedical and Life Sciences; Biomedicine; Disease control; Fatalities; FDA approval; Fever; Histopathology; Infectious Diseases; Medical Microbiology; Nosocomial infections; Pathogens; Pathology; Public Health; RNA polymerase; Vaccine; Vaccines; Virology; Viruses
• ISSN: 2059-0105; 2059-0105
• DOI: 10.1038/s41541-024-00877-1

Crimean-Congo hemorrhagic fever virus (CCHFV) can cause severe human disease and is considered a WHO priority pathogen due to the lack of efficacious vaccines and antivirals. A CCHF virus replicon particle (VRP) has previously shown protective efficacy in a lethal Ifnar -/- mouse model when administered as a single dose at least 3 days prior to challenge. Here, we determine that non-specific immune responses are not sufficient to confer short-term protection, since Lassa virus VRP vaccination 3 days prior to CCHFV challenge was not protective. We also investigate how CCHF VRP vaccination confers protective efficacy by examining viral kinetics, histopathology, clinical analytes and immunity early after challenge (3 and 6 days post infection) and compare to unvaccinated controls. We characterize how these effects differ based on vaccination period and correspond to previously reported CCHF VRP-mediated protection. Vaccinating Ifnar -/- mice with CCHF VRP 28, 14, 7, or 3 days prior to challenge, all known to confer complete protection, significantly reduced CCHFV viral load, mucosal shedding, and markers of clinical disease, with greater reductions associated with longer vaccination periods. Interestingly, there were no significant differences in innate immune responses, T cell activation, or antibody titers after challenge between groups of mice vaccinated a week or more before challenge, but higher anti-NP antibody avidity and effector function (ADCD) were positively associated with longer vaccination periods. These findings support the importance of antibody-mediated responses in VRP vaccine-mediated protection against CCHFV infection.